Project Grant R01NS136523

Award Date 4/1/25
Completion Date 2/28/30
Dollars Obligated $654K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This $667,644 Project Grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research into cortical demyelination and repair in early multiple sclerosis (MS). The awardee, Icahn School of Medicine at Mount Sinai, will conduct a 3-year longitudinal study to investigate the relationship between cortical and white matter demyelination in early MS,...
This federal Project Grant award, worth $694,369, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports a multi-scale, multi-modal imaging study to examine the association between cognitive decline and changes in brain structure, function, and neuronal integrity in patients with multiple sclerosis (MS). The primary awardee, Weill...
This Project Grant award in the amount of $398,690.00 was made on April 16, 2024 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The award supports research focused on understanding the role of microglia, the innate immune cells of the central nervous system, in cortical remyelination and the regeneration of oligodendrocytes in the context of...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), will provide $949,181 to the Icahn School of Medicine at Mount Sinai to fund research on the association between cortical lesions and physical/cognitive disability in multiple sclerosis using novel MRI methods. The research aims to advance the clinical understanding and treatment of multiple sclerosis, with a performance period from August 15, 2024 to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $742,352 to New York University School of Medicine to conduct a collaborative, community-engaged research study on the relationship between childhood adversity and health outcomes for individuals with multiple sclerosis (MS), particularly among high-risk minority populations. The 5-year...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund a $353,942 research project by Microstructure Imaging Inc. to develop quantitative magnetic resonance imaging (MRI) biomarkers for staging and monitoring multiple sclerosis (MS). The key products and services to be delivered under this award include: Curating a...
The federal Project Grant award (R21NS136961) for $241,500 from the National Institute of Neurological Disorders and Stroke (NINDS) Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research to investigate changes in spinal cord structure and function in multiple sclerosis (MS) patients using 7T MRI imaging. The key objectives are to (1) determine if intermediate lesions, characterized by axonal degeneration, can be distinctly detected from...
This $647,782 five-year Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research to evaluate the therapeutic potential of hypoxia mimetics in treating inflammatory demyelinating diseases like multiple sclerosis (MS). The awardee, San Diego Biomedical Research Institute, will conduct studies to define an optimal treatment protocol using hypoxia...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $930,825 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The funding will be used to develop and optimize a high-throughput screening assay (OPC-X screen) to identify small molecule compounds that can overcome the inhibition of remyelination caused...
This $2,011,345 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research at the Icahn School of Medicine at Mount Sinai (ISMMS) to examine the impact of Alzheimer's disease pathology on frontal-sensory neural circuits and cognitive control. The research aims to: 1) analyze how amyloid-beta accumulation disrupts top-down frontal-sensory projections, 2) investigate the effects on frontal cholinergic neuromodulation, and 3) determine how the...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $654,287 to the Icahn School of Medicine at Mount Sinai for a research project titled "Computational Model of Neurocognitive Impairment in Multiple Sclerosis." The goal of this 5-year project is to develop a psychometrically valid and biologically informed computational model to characterize cognitive deficits in relapsing-remitting and progressive multiple sclerosis. The project aims to translate cognitive psychology and computational modeling approaches to reappraise the longstanding speed-centric model of cognition in MS, and investigate the predictive value of specific cognitive processing components in relation to brain pathology, patient-reported outcomes, and performance in other cognitive domains. This award will fund research activities to advance the scientific understanding of cognitive impairment in present-day MS and inform the development of targeted treatments.

Generated 4/8/25, 5:32 AM